Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Receivables Refunds Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt issuances

Ratios

Tvardi Therapeutics (TVRD) Shares Issued (2016 - 2025)

Tvardi Therapeutics' Shares Issued history spans 11 years, with the latest figure at $1000.0 for Q4 2025.

On a quarterly basis, Shares Issued changed N/A to $1000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $108000.0, a 80.61% decrease, with the full-year FY2025 number at $532000.0, up 10540.0% from a year prior.
Shares Issued hit $1000.0 in Q4 2025 for Tvardi Therapeutics, down from $107000.0 in the prior quarter.
Over the last five years, Shares Issued for TVRD hit a ceiling of $1.1 million in Q3 2023 and a floor of -$560000.0 in Q4 2023.
Historically, Shares Issued has averaged $244230.8 across 4 years, with a median of $182000.0 in 2022.
The widest YoY moves for Shares Issued: up 18566.67% in 2023, down 2645.45% in 2023.
Tracing TVRD's Shares Issued over 4 years: stood at $319000.0 in 2021, then crashed by 93.1% to $22000.0 in 2022, then crashed by 2645.45% to -$560000.0 in 2023, then soared by 100.18% to $1000.0 in 2025.
Business Quant data shows Shares Issued for TVRD at $1000.0 in Q4 2025, $107000.0 in Q3 2025, and -$560000.0 in Q4 2023.